Steigerwald Gordon & Koch Inc. Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Steigerwald Gordon & Koch Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 112,353 shares of the company’s stock after selling 75 shares during the quarter. Johnson & Johnson makes up approximately 2.1% of Steigerwald Gordon & Koch Inc.’s investment portfolio, making the stock its 24th largest position. Steigerwald Gordon & Koch Inc.’s holdings in Johnson & Johnson were worth $18,633,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in JNJ. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $32,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $33,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Johnson & Johnson in the fourth quarter worth about $36,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $153.39 on Thursday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company’s 50 day moving average is $153.81 and its 200 day moving average is $153.67. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market cap of $369.07 billion, a PE ratio of 23.07, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.39%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is 57.84%.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 16th. Barclays decreased their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Finally, Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.